FDA 483 - Carlos Timaran, MD - January 15, 2026

An FDA inspection of Mirza S. Baig, MD, Clinical Investigator in Dallas, TX, revealed significant deficiencies in the conduct of a clinical study. The firm failed to promptly report serious adverse events to the Institutional Review Board and maintained inaccurate and incomplete subject case history records. These issues indicate a lack of adherence to investigational plans and proper documentation practices.